Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JRVR, QFIN and ITRM

Sunday, 29 August 2021 11:45 AM

The Klein Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / August 29, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

James River Group Holdings, Ltd. (NASDAQ:JRVR) 
Class Period: August 1, 2019 - May 5, 2021
Lead Plaintiff Deadline: September 7, 2021

James River Group Holdings, Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) James River had not adequately reserved for its Uber policies; (2) James River was using an incorrect methodology for setting reserves that materially understated the Company's true exposure to Uber claims; (3) as a result, James River was forced to increase its unfavorable reserves in subsequent quarters even after cancelling the Uber policies; and (4) as a result of the foregoing, Defendants' statements about James River's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in JRVR : https://www.kleinstocklaw.com/pslra-1/james-river-group-holdings-ltd-loss-submission-form?id=19083&from=1

360 DigiTech, Inc. (NASDAQ:QFIN) 
Class Period: April 29, 2021 - July 7, 2021
Lead Plaintiff Deadline: September 13, 2021

The QFIN lawsuit alleges 360 DigiTech, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in QFIN : https://www.kleinstocklaw.com/pslra-1/360-digitech-inc-loss-submission-form?id=19083&from=1

Iterum Therapeutics Plc (NASDAQ:ITRM) 
Class Period: November 30, 2020 - July 23, 2021
Lead Plaintiff Deadline: October 4, 2021

Throughout the class period, Iterum Therapeutics Plc allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ITRM : https://www.kleinstocklaw.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?id=19083&from=1

The Klein Law Firm, Sunday, August 29, 2021, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected] 
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: